©1996 by The American Society for Biochemistry and Molecular Biology, Inc.
Physical and Functional Association of Cortactin with Syk in Human Leukemic Cell Line K562 (*)

(Received for publication, July 31, 1995; and in revised form, December 12, 1995)

Shingo Maruyama Tomohiro Kurosaki (3) Kiyonao Sada (1) Yuji Yamanashi (2) Tadashi Yamamoto (2) Hirohei Yamamura (1)(§)

From the  (1)Department of Biochemistry, Fukui Medical School, Matsuoka, Fukui 910-11, the Department of Biochemistry, Kobe University School of Medicine, Chuo-ku, Kobe 650, and the (2)Department of Oncology, Institute of Medical Science, University of Tokyo, 4-6-1, Shirokanedai, Minatoku, Tokyo 108, Japan, the (3)Department of Cardiovascular Molecular Biology, Lederle Laboratories, Pearl River, New York 10965, and the Section of Immunobiology, Yale University School of Medicine, New Haven, Connecticut 06510-8023

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES

ABSTRACT

Human leukemic cell line K562 is induced to differentiate into the megakaryocytic lineage by stimulation with 12-O-tetradecanoylphorbol-13-acetate (TPA). We demonstrate here that TPA stimulation increases tyrosine phosphorylation of an 80-kDa protein at an early stage of megakaryocytic differentiation and that this 80-kDa protein is identical with cortactin. Since tyrosine kinase Syk was activated by TPA stimulation, we examined the possibility that cortactin is a potential substrate of Syk in K562 cells. TPA-induced tyrosine phosphorylation of cortactin was decreased profoundly by overexpression of dominant-negative Syk. Furthermore, cortactin was associated with Syk even before TPA stimulation. Since cortactin was previously referred as an 80/85-kilodalton pp60 substrate, we examined the association between Src and cortactin, whereas its association could not be detected. These data suggest that Syk phosphorylates cortactin in K562 cells upon TPA treatment.


INTRODUCTION

The generation of functional cells of the hematopoietic system is a complex process requiring both the constant production of large numbers of differentiated cells and the maintenance of primitive precursor cells. As model systems to investigate the mechanisms of hematopoietic differentiation, several hematopoietic cell lines that can be induced to various cell lineages have been used. In these cell lines, K562 cells, established from a patient with chronic myeloid leukemia in blast crisis(1) , have a potential to differentiate into a variety of hematopoietic cell lineages(2, 3, 4, 5, 6, 7, 8, 9) . Several lines of evidence indicate that this cell line can be differentiated into megakaryocytic lineage by stimulation with 12-O-tetradecanoylphorbol-13-acetate (TPA)(^1)(6, 10) . The expression of platelet glycoprotein IIIa (GPIIIa) and thromboxane A(2) receptor, which have been used as a marker of megakaryocytic differentiation, is strongly enhanced on the surface of K562 cells upon treatment with TPA (11, 12) . Furthermore, during TPA induction, nuclear DNA ploidy of these cells is increased to 4-16n simultaneously with an increase in cell volume(13, 14) . K562 cells can also be induced to undergo erythroid differentiation by various compounds, including hemin(2) . When K562 cells are treated by hemin, the transcription of -, -, -, and alpha-globin mRNA is increased (15, 16) and hemoglobin is accumulated(2, 17) .

Evidence has been accumulating that protein tyrosine phosphorylation and dephosphorylation play important roles in a variety of processes, leading to cell growth and differentiation in hematopoietic cells. Indeed, K562 cells transfected with c-fes, one of the non-receptor-type protein-tyrosine kinases, undergo myeloid differentiation(18) . In contrast, erythroid differentiation of these cells can be induced by herbimycin A, an inhibitor of tyrosine kinase (19) . A non-receptor-type protein-tyrosine kinase Syk is expressed in almost all the hematopoietic cells. Although the functions of Syk in mast cell, B cell, and platelet activation have been elucidated extensively(20) , its roles in hematopoietic cell differentiation remain to be addressed. We found here that an 80-kilodalton (kDa) protein, cortactin, is tyrosine-phosphorylated in K562 cells upon TPA treatment, and cortactin associates physically and functionally with Syk. These findings suggest that Syk mediates tyrosine phosphorylation of cortactin at an early stage of megakaryocytic differentiation in K562 cells.


EXPERIMENTAL PROCEDURES

Cell Culture

K562 cells were cultured in RPMI 1640 supplemented with 10% heat-inactivated fetal bovine serum, 100 IU/ml penicillin, and 100 µg/ml streptomycin. Passages were performed every 3 days when the cells were in exponential phase of growth. The cells were induced to differentiation by adding 10 nM TPA and harvested at the indicated times. The differentiation of stimulated cells was confirmed by Giemsa staining.

Antibodies

Antibody (Ab) against porcine Syk was generated by immunizing rabbit with synthesized peptides as described(21) . The sequence of synthesized peptides to generate anti-porcine Syk Ab is not conserved in human Syk, so this Ab reacts specifically with porcine Syk. Monoclonal Ab (mAb) against human Syk (101) was obtained from Wako Chemicals, Tokyo, Japan. Anti-human retinoblastoma protein (Rb) mAb (G99-2005) was purchased from Pharmingen. Anti-phosphotyrosine mAb (4G10), anti-cortactin mAb (anti-p80/85 pp60 substrate, 4F11), and anti-Src mAb (GD11) were purchased from Upstate Biotechnology, Inc.

Generation of Dominant-negative Mutant

A point mutation (Lys Arg) in the ATP binding site of porcine syk cDNA was created by polymerase chain reaction as described(22) , and this mutated cDNA was inserted into the EcoRI site of pApuro vector, harboring the chicken actin promoter and puromycin-resistant gene. This plasmid was linearized and transfected into human hematopoietic cell line K562 cells by electroporation using Electroporator II (Invitrogen) at 300 V, 1000 microfarads, and selected in the presence of 1.0 µg/ml puromycin. Cells were cloned by limiting dilution, and the expression of transfected cDNA was confirmed by immunoblot analysis using anti-porcine Syk Ab.

Immunoprecipitation and in Vitro Kinase Assay

Cells were sedimented by centrifugation and the pellets were solubilized in Nonidet P-40 lysis buffer (1% Nonidet P-40, 20 mM Tris, pH 7.5, 150 mM NaCl, 10 mM EDTA, 100 mM NaF, 1 mM vanadate) supplemented with 2 mM phenylmethylsulfonyl fluoride and 10 µg/ml leupeptin. The lysates were incubated with Ab-conjugated protein A-Sepharose for 1 h at 4 °C. The immunoprecipitates were washed three times with lysis buffer and twice with 10 mM HEPES, pH 8.0. Each sample was incubated in 60 µl of reaction mixture (45 mM HEPES, pH 8.0, 150 mM NaCl, 50 mM MgCl(2), 10 µM vanadate, 1 µM ATP) containing 5 µCi of [-P]ATP with 0.2 mg/ml H2B histone or 0.04 mg/ml of acid-treated enolase. After 10 min at 30 °C, the reaction was terminated by adding Laemmli SDS sample buffer and boiling for 3 min. The samples were separated on SDS-PAGE gels and analyzed using a Fujix imaging analyzer (BAS 2000).

To examine the association of Syk with cortactin, digitonin lysis buffer (1% digitonin, 50 mM Tris, pH 7.5, 150 mM NaCl, 5 mM EDTA, 100 µM vanadate) supplemented with 2 mM phenylmethylsulfonyl fluoride and 10 µg/ml leupeptin was used instead of Nonidet P-40 lysis buffer. After washing, immunoprecipitates were boiled with Laemmli SDS sample buffer and subjected to immunoblot analysis.

Immunoblot Analysis

Whole cell lysates were prepared from nonstimulated or stimulated cells by boiling with Laemmli SDS sample buffer for 3 min. Whole cell lysates or immunoprecipitates were separated on SDS-PAGE gels and transferred onto polyvinylidene difluoride membrane. The blots were blocked with 5% milk, 0.05% Tween 20 in phosphate-buffered saline and incubated with primary Ab for 1 h at room temperature. After washing with 0.05% Tween 20 in phosphate-buffered saline, filters were developed with goat anti-mouse or donkey anti-rabbit secondary Ab conjugated to horseradish peroxidase.


RESULTS

Tyrosine phosphorylation in K562 cells following TPA stimulation was assessed by immunoblot analysis of whole cell lysates with anti-phosphotyrosine mAb. Following TPA stimulation, cells were harvested at the indicated times, and whole cell lysates were resolved by SDS-PAGE and subjected to immunoblot analysis with anti-phosphotyrosine mAb. As shown in Fig. 1, a protein with molecular mass of 80 kDa was tyrosine-phosphorylated, reaching a maximum within 10 min. Two other phosphotyrosine-containing proteins, approximately 160 and 110 kDa, were dephosphorylated with different time courses after TPA stimulation.


Figure 1: Tyrosine phosphorylation following TPA stimulation in K562 cells. K562 cells were stimulated by 10 nM TPA and solubilized at the indicated times. Whole cell lysates were separated on 12% SDS-PAGE gel and subjected to immunoblot analysis probed with anti-phosphotyrosine mAb. The positions of the molecular markers are shown to the left in kDa. Arrowheads indicate the positions of the 160-, 110-, and 80-kDa proteins, respectively.



To identify this 80-kDa protein, we performed immunoblot analysis with several Abs to known phosphoproteins of similar size. Among various Abs tested, we found that this 80-kDa protein migrates to the same mobility as cortactin. Fig. 2A shows immunoblotting of whole cell lysates with anti-phosphotyrosine mAb or anti-cortactin mAb. By long time development, the lower extra band was visualized. To confirm that this 80-kDa protein is cortactin, immunoblotting of anti-cortactin immunoprecipitates with anti-phosphotyrosine mAb was carried out. As shown in Fig. 2B, tyrosine phosphorylation of cortactin was induced by TPA stimulation. The amount of precipitated cortactin did not differ in both samples judging from the immunoblot analysis with anti-cortactin mAb. We next performed depletion experiments with anti-cortactin mAb. TPA-induced tyrosine phosphorylation of the 80-kDa protein was not detected following depletion with anti-cortactin Ab, whereas it was not affected by the depletion with same isotype-irrelevant mAb, anti-Rb mAb (Fig. 2C). These results demonstrate that this 80-kDa protein is identical with cortactin.


Figure 2: Tyrosine phosphorylation of cortactin in K562 cells. A, whole cell lysates were separated on 12% SDS-PAGE gel and blotted on membrane. Blotted membrane was cut into two pieces, and one membrane was probed with anti-phosphotyrosine mAb and the other membrane was probed with anti-cortactin mAb. The positions of molecular markers are shown to the left in kDa. The arrowhead indicates the position of the 80-kDa protein. B, tyrosine phosphorylation of cortactin in K562 cells. a, cells were stimulated by 10 nM TPA for 20 min. Stimulated and unstimulated cells were solubilized and immunoprecipitated with anti-cortactin mAb. Immunoprecipitates were subjected to immunoblot analysis probed with anti-phosphotyrosine mAb. b, each immunoprecipitated sample was subjected to immunoblot analysis with anti-cortactin mAb. The positions of cortactin and immunoglobulin heavy chain are indicated. C, depletion of cortactin from TPA-stimulated cells. Cells were stimulated as above, and cell lysates were obtained before (pre IP) and after immunoprecipitation with anti-cortactin mAb or the same isotype-irrelevant mAb, anti-Rb mAb. Lysates were separated on 12% SDS-PAGE gel and subjected to immunoblot analysis with anti-phosphotyrosine mAb. The positions of molecular markers are shown to the left in kDa. The arrowhead indicates the position of 80 kDa.



A report that cortactin is tyrosine-phosphorylated after stimulation of platelets with thrombin(23) , together with the observation that this stimulant activates Syk(21) , prompted us to examine the involvement of Syk in TPA-induced tyrosine phosphorylation in K562 cells. We first examined whether TPA activates Syk in this cell line or not. After TPA stimulation, cells were solubilized with Nonidet P-40 lysis buffer at the indicated times, and Syk was immunoprecipitated by anti-human Syk mAb. Then, an in vitro kinase assay was performed with an exogenous substrate H2B histone. Syk kinase activity was increased within 1 min and reached to a maximum at 5 min after TPA stimulation (Fig. 3A). The amount of precipitated Syk did not change throughout the time course judging from the immunoblot analysis with anti-human Syk mAb (Fig. 3B).


Figure 3: Activation of Syk kinase in response to addition of TPA. A, K562 cells were stimulated by 10 nM TPA and solubilized at the indicated times. Syk was immunoprecipitated with anti-human Syk mAb and subjected to an in vitro kinase assay using H2B histone as an exogenous substrate. B, each immunoprecipitated sample was subjected to immunoblot analysis with anti-human Syk mAb. The positions of Syk and H2B histone are indicated.



To address the relation between Syk activation and phosphorylation of cortactin in TPA-treated K562 cells, cell lines expressing a dominant-negative mutant form of Syk were established. A point mutation was created in the ATP binding site of porcine syk cDNA, leading to loss of its kinase activity, Syk(K)(22) . This mutated cDNA was transfected into K562 cells, and stable transformants were isolated in the presence of puromycin. Expression of mutated porcine Syk was examined by immunoblot analysis with anti-Syk Ab which recognizes only porcine species, and 4 stable transformants were cloned. Fig. 4A shows the expression of mutated porcine Syk in 2 clones of Syk(K) expressing cells. To examine whether overexpression of Syk(K) affects tyrosine phosphorylation in K562 cells, whole cell lysates of stimulated and unstimulated cells were subjected to immunoblot analysis with anti-phosphotyrosine mAb. In parental K562 cells, an 80-kDa protein was tyrosine-phosphorylated by TPA stimulation, whereas in 4 transformants expressing Syk(K), this induction was abolished. Fig. 4B shows tyrosine phosphorylation of the 80-kDa protein in parental K562 cells and 2 clones of Syk(K) expressing cells. To confirm that this 80-kDa protein is cortactin, cell lysates from parental K562 cells and transformant expressing Syk(K) were immunoprecipitated by anti-cortactin Ab and probed with anti-phosphotyrosine mAb (Fig. 4C). Consistent with a whole cell lysate data, TPA-induced tyrosine phosphorylation of cortactin was not observed in transformant expressing Syk(K). These data demonstrate a strong correlation between Syk activity and TPA-induced tyrosine phosphorylation of cortactin.


Figure 4: Expression of kinase-negative Syk in K562 cells. K562 cells were transfected with kinase-negative porcine syk cDNA in which a point mutation was created in the ATP binding site. Transfected cells were selected in the presence of puromycin and cloned by limiting dilution. A, expression of transfected cDNA. Whole cell lysates of wild type K562 (Wt) and 2 clones of Syk(K) transfected cells were analyzed by immunoblot analysis with anti-porcine Syk Ab. B, tyrosine phosphorylation of wild type K562 (Wt) and 2 clones of Syk(K) transfected cells following TPA stimulation. Whole cell lysates of nonstimulated cells and TPA-stimulated cells were subjected to immunoblot analysis with anti-phosphotyrosine mAb. Stimulation was performed by adding 10 nM TPA for 20 min. The positions of the molecular markers are shown to the left in kDa. The arrowhead indicates the position of 80 kDa. C, tyrosine phosphorylation of cortactin in wild type and Syk(K) expressing cells. a, cortactin before and after stimulation in these cells was immunoprecipitated, followed by immunoblot analysis with anti-phosphotyrosine mAb. b, each immunoprecipitated sample was subjected to immunoblot analysis with anti-cortactin mAb. The positions of cortactin and immunoglobulin heavy chain are indicated.



To get insights of whether Syk directly or indirectly phosphorylates cortactin upon TPA treatment, co-immunoprecipitation experiments were performed. K562 cells were stimulated and Syk was immunoprecipitated as described in Fig. 3with a modification that digitonin lysis buffer was used to solubilize cells instead of Nonidet P-40 lysis buffer. Immunoprecipitates were subjected to immunoblot analysis with anti-cortactin mAb. As shown in Fig. 5, cortactin was co-immunoprecipitated with Syk both before and after stimulation. The amount of cortactin was not different throughout the time course. Although the isotype of anti-human Syk mAb has not been determined, we conveniently used anti-human Rb mAb for negative control immunoprecipitation to exclude the possibility that cortactin binds nonspecifically to protein A. Co-precipitation of cortactin with Syk was also found when Nonidet P-40 lysis buffer was used to solubilize cell lysates (data not shown), demonstrating that this association is stable. The amount of precipitated Syk did not differ throughout the time course (data not shown). Syk could not be detected in the precipitates with anti-cortactin mAb. One possibility is that as anti-human Syk mAb is not so suitable for immunoblot analysis, we could not detect a small amount of co-precipitated Syk. Another possibility is that the amount of cortactin might be greater than that of Syk in this cell, and cortactin that does not associate with Syk might be present. So, a detectable amount of Syk could not be precipitated with cortactin.


Figure 5: Association of cortactin with Syk. K562 cells were stimulated and Syk was immunoprecipitated as described in Fig. 3with a modification that digitonin lysis buffer was used instead of Nonidet P-40 lysis buffer. Immunoprecipitates were subjected to immunoblot analysis with anti-cortactin mAb. For irrelevant Ab negative control, anti-Rb mAb was used. The positions of cortactin and immunoglobulin heavy chain are indicated.



Since cortactin has been reported to be a potential substrate of Src, we assessed the kinase activity of Src following TPA stimulation in wild type cells and Syk(K) expressing cells. As shown in Fig. 6A, both in K562 cells and transformant expressing Syk(K), autophosphorylation of Src and phosphorylation of enolase were increased after addition of TPA, suggesting that Syk activity does not affect TPA-induced activation of Src. The amount of precipitated Src did not differ in each sample (Fig. 6B). In the same condition for detecting the association of cortactin with Syk, its association with Src could not be detected (data not shown).


Figure 6: Activation of Src kinase in response to addition of TPA. A, K562 and Syk(K) expressing cells were stimulated by 10 nM TPA for the indicated times. Src was immunoprecipitated by anti-Src mAb, and in vitro kinase assay was performed with enolase as an exogenous substrate. B, each immunoprecipitated sample was subjected to immunoblot analysis with anti-Src mAb. The positions of Src, enolase, and immunoglobulin heavy chain are indicated.




DISCUSSION

In this study, we demonstrate that cortactin is tyrosine-phosphorylated following TPA stimulation in K562 cells by using immunoprecipitation experiments. TPA is well known to be an activator of protein kinase C, suggesting that the protein kinase C activates tyrosine kinase(s), leading to the induction of tyrosine phosphorylation of cortactin. TPA-induced tyrosine phosphorylation was reported(24, 25, 26, 27, 28, 29, 30, 31, 32) , whereas it was not necessarily elucidated whether this process is mediated by protein kinase C. It was reported that the biological effects by TPA cannot be explained completely by protein kinase C activation in K562 cells(33, 34, 35, 36) . It is also possible that TPA-induced tyrosine phosphorylation of cortactin is independent of protein kinase C activation.

Cortactin was initially described as an 80/85-kilodalton pp60 substrate. It became phosphorylated on tyrosine residues in v-Src-transformed chicken embryo (CE) cells(37) . In normal cells, cortactin is known to be tyrosine-phosphorylated by various stimulants including growth factors and thrombin(23, 38, 39, 40) . Since Src is recruited to growth factor receptors possessing tyrosine kinase in those cytoplasmic domains by SH2 domain/phosphotyrosine interactions and consequently activated, it was proposed that cortactin is phosphorylated by this activated Src(40) . However, it has been noted previously that cortactin could not be detected in Src immunoprecipitates, and involvement of other tyrosine kinase(s) in tyrosine phosphorylation of cortactin has been suggested(37, 41, 42, 43) . In platelets, tyrosine phosphorylation of cortactin and activation of Syk were induced by thrombin treatment, although a direct correlation between these events was not clarified. We show here a possibility that cortactin is a substrate of Syk upon TPA stimulation by the following evidence. 1) Syk is activated by TPA stimulation, and, following the activation of Syk, cortactin is tyrosine-phosphorylated. 2) Expression of dominant-negative Syk abolishes the TPA-induced tyrosine phosphorylation of cortactin. 3) Cortactin is associated with Syk even before TPA stimulation. Since Src is also activated by TPA stimulation, it is possible that cortactin is a direct substrate of Src in TPA-treated K562 cells. However, in contrast to the association of cortactin with Syk, we could not detect the association of cortactin with Src, suggesting that it is unlikely that Src phosphorylates cortactin directly.

An interaction between Syk and Src family protein-tyrosine kinases has been proposed(44) . Coexpression of Src family protein-tyrosine kinases and Syk leads to a remarkable increase in net tyrosine phosphorylation, whereas Src family protein-tyrosine kinases or Syk alone induce only marginal phosphorylation in COS cells. Our finding that TPA-induced Src activation is not affected by overexpression of dominant-negative Syk may exclude the possibility that Syk activates Src kinase activity, resulting in tyrosine phosphorylation of cortactin. It would be less possible that Syk and Src are activated independently, considering the close relationship between Syk and Src or Src and cortactin. Src might be upstream to Syk.

As mentioned, TPA treatment of K562 cells induces the increase of nuclear DNA ploidy and cell volume. Cortactin is concentrated in a cytoskeleton-associated structure that is rich in focal adhesion proteins(37) . Since cortactin is able to associate with F-actin through its tandem helix-turn-helix domain(41) , it may be conceivable that cortactin is involved in this TPA-mediated morphological change.

Cortactin is related to a putative transcriptional factor HS1(45) . This protein is specifically expressed in hematopoietic cells and functions as a major substrate of protein-tyrosine kinase(s) involved in B-cell antigen receptor-mediated signaling. Tyrosine-phosphorylated HS1 is demonstrated to be localized mainly in nucleus, proposing the idea that HS1 is translocated from the cytoskeleton to the nucleus through its phosphorylation(46, 47) . Similarly, cortactin may be transported to the nucleus through its tyrosine phosphorylation where it may be involved in nuclear events such as transcriptional regulation, leading to differentiation into megakaryocytic lineage. Although these notions await further investigation, the present study demonstrates that cortactin may be the substrate of Syk rather than Src.


FOOTNOTES

*
This study was supported by grants-in-aid for general scientific research, for scientific research on priority areas, and for international scientific research from the Ministry of Education, Science and Culture, Japan and the Yamanouchi Foundation for Research on Metabolic Disorders. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§
To whom correspondence should be addressed. Tel.: 81-78-341-7451; Fax: 81-78-371-8734.

(^1)
The abbreviations used are: TPA, 12-O-tetradecanoylphorbol-13-acetate; PAGE, polyacrylamide gel electrophoresis; Ab, antibody; mAb, monoclonal antibody; Rb, retinoblastoma protein; Syk(K), kinase-negative Syk; SH2, Src homology 2.


ACKNOWLEDGEMENTS

We thank Dr. M. Asahi for 4G10. We also thank Dr. T. Nogochi for helpful advice and K. Sakai for her skillful secretarial assistance.


REFERENCES

  1. Lozzio, C. B., and Lozzio, B. B. (1975) Blood 45, 321-334 [Abstract]
  2. Rutherford, T. R., Clegg, J. B., and Weartherall, D. J. (1979) Nature 280, 164-165 [Medline] [Order article via Infotrieve]
  3. Rowley, P. T., Ohlsson-Wilhelm, E. M., Farley, B. A., and LaBella, S. (1981) Exp. Hematol. 9, 32-37 [Medline] [Order article via Infotrieve]
  4. Vainchenker, W., Testa, U., Guichard, J., Titeux, M., and Breton-Gorius, J. (1981) Blood Cells 7, 357-375 [Medline] [Order article via Infotrieve]
  5. Tonkonow, B. L., Hoffman, R., Burger, D., Elder, J. T., Mazur, E. M., Murnane, M. J., and Benz, E. J., Jr. (1982) Blood 59, 738-746 [Abstract]
  6. Villeval, J. L., Pelicci, P., Tabillo, A., Titeux, M., Henri, A., Houesche, F., Thomopoulos, P., Vainchenker, W., Rochant, H., Breton-Gorius, J., Edwards, P. A. W., and Testa, U. (1983) Exp. Cell Res. 146, 428-435 [Medline] [Order article via Infotrieve]
  7. Tabillo, A., Pelicci, P. G., Vinci, G., Mannoni, P., Civin, C. I., Vainchenker, W., Testa, U., Lipinski, M., Rochant, H., and Breton-Gorius, J. (1983) Cancer Res. 43, 4569-4574 [Abstract]
  8. Luisi-DeLuca, C., Mitchell, T., Spriggs, D., and Kuffe, D. W. (1984) J. Clin. Invest. 74, 821-827 [Medline] [Order article via Infotrieve]
  9. Sutherland, J. A., Turner, A. R., Mannoni, P., McGann, L. E., and Turc, J. M. (1986) J. Biol. Response Modif. 5, 250-262 [Medline] [Order article via Infotrieve]
  10. Siebert, P., and Fukuda, M. (1985) Prog. Clin. Biol. Res. 191, 233-248 [Medline] [Order article via Infotrieve]
  11. Tetteroo, P. A., Massaro, F., Mulder, A., Schreuder-van Gelder, R., and von dem Borne, A. E. (1984) Leukemia Res. 8, 197-206 [Medline] [Order article via Infotrieve]
  12. Nakajima, M., Yamamoto, M., Ushikubi, F., Okuma, M., Fujiwara, M., and Narumiya, S. (1989) Biochem. Biophys. Res. Commun. 158, 958-965 [Medline] [Order article via Infotrieve]
  13. Leary, J . F., Farley, B. A., Guiliano, R., Kosciolek, B. A., La Bella, S., and Rowley, P. T. (1987) J. Biol. Regul. Homeostatic Agents 1, 73-80
  14. Alitalo, R. (1990) Leukemia Res. 14, 501-514 [Medline] [Order article via Infotrieve]
  15. Charnay, P., and Maniatis, T. (1983) Science 220, 1281-1283 [Medline] [Order article via Infotrieve]
  16. Dean, A., Ley, T. J., Humphries, R. K., Fordis, M., and Schechter, A. N. (1983) Proc. Natl. Acad. Sci. U. S. A. 80, 5515-5519 [Abstract]
  17. Rutherford, T. R., Clegg, J. B., Higgs, D. R., Jones, R. W., Thompson, J., and Weartherall, D. J. (1981) Proc. Natl. Acad. Sci. U. S. A. 78, 348-352 [Abstract]
  18. Yu, G., Smithgall, T. E., and Glazer, R. I. (1989) J. Biol. Chem. 264, 10276-10281 [Abstract/Free Full Text]
  19. Honma, Y., Okabe-Kado, J., Hozumi, M., Uehara, Y., and Mizuno, S. (1989) Cancer Res. 49, 331-334 [Abstract]
  20. Yanagi, S., Kurosaki, T., and Yamamura, H. (1995) Cell Signalling 7, 185-193 [CrossRef][Medline] [Order article via Infotrieve]
  21. Taniguchi, T., Kitagawa, H., Yasue, S., Yanagi, S., Sakai, K., Asahi, M., Ohta, S., Takeuchi, F., Nakamura, S., and Yamamura, H. (1993) J. Biol. Chem. 268, 2277-2279 [Abstract/Free Full Text]
  22. Takata, M., Sabe, H., Hata, A., Inazu, T., Homma, Y., Nukada, T., Yamamura, H., and Kurosaki, T. (1994) EMBO J. 13, 1341-1349 [Abstract]
  23. Wong, S., Reynolds, A. B., and Papkoff, J. (1992) Oncogene 7, 2407-2415 [Medline] [Order article via Infotrieve]
  24. Gilmore, T., and Martin, S. (1983) Nature 306, 487-490 [Medline] [Order article via Infotrieve]
  25. Cooper, J. A., Sefton, B. M., and Hunter, T. (1984) Mol. Cell. Biol. 4, 30-37 [Medline] [Order article via Infotrieve]
  26. Barnekow, A., and Gessler, M. (1986) EMBO J. 5, 701-705 [Abstract]
  27. Golden, A., and Brugge, J. S. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 901-905 [Abstract]
  28. Filvaroff, E., Stern, D. F., and Dotto, G. P. (1990) Mol. Cell. Biol. 10, 1164-1173 [Medline] [Order article via Infotrieve]
  29. Einspahr, K. J., Abraham, R. T., Dick, C. J., and Leibson, P. J. (1990) J. Immunol. 145, 971-979 [Abstract/Free Full Text]
  30. Force, T., Kyriakis, J. M., Avruch, J., and Bonventre, J. V. (1991) J. Biol. Chem. 266, 6650-6656 [Abstract/Free Full Text]
  31. Katagiri, K., Katagiri, T., Kajiyama, K., Yamamuto, T., and Yoshida, T. (1993) J. Immunol. 150, 585-593 [Abstract/Free Full Text]
  32. Li, W., Mischak, H., Yu, J. C., Wang, L. M., Mushinski, J. F., Heidaran, M. A., and Pierce, J. H. (1994) J. Biol. Chem. 269, 2349-2352 [Abstract/Free Full Text]
  33. Hoffman, R., and Newlands, E. S. (1991) Cancer Chemother. Pharmacol. 28, 102-104 [Medline] [Order article via Infotrieve]
  34. Meichle, A., Schutze, S., Hensel, G., Brunsing, D., and Kronke, M. (1990) J. Biol. Chem. 265, 8339-8343 [Abstract/Free Full Text]
  35. Katayama, N., Nishikawa, M., Minami, M., and Shirakawa, S. (1989) Blood 73, 123-130 [Abstract]
  36. Yen, A., Varvayanis, S., and Platko, J. D. (1993) Cancer Res. 53, 3085-3091 [Abstract]
  37. Wu, H., Reynold, A. B., Kanner, S. B., Vines, R. R., and Parsons, J. T. (1991) Mol. Cell. Biol. 11, 5113-5124 [Medline] [Order article via Infotrieve]
  38. Maa, M. C., Wilson, L. K., Moyers, J. S., Vines, R. R., Parsons, J. T., and Parsons, S. J. (1992) Oncogene 7, 2429-2438 [Medline] [Order article via Infotrieve]
  39. Durieu-Trautmann, O., Chaverot, N., Cazaubon, S., Strosberg, A. D., and Couraud, P. O. (1994) J. Biol. Chem. 269, 12536-12540 [Abstract/Free Full Text]
  40. Zhan, X., Plourde, C., Hu, X., Friesel, R., and Maciag, T. (1994) J. Biol. Chem. 269, 20221-20224 [Abstract/Free Full Text]
  41. Wu, H., and Parsons, J. T. (1993) J. Cell Biol. 120, 1417-1426 [Abstract]
  42. Schuuring, E., Verhoeven, E., Mooi, W. J., and Michalides, R. J. (1992) Oncogene 7, 355-361 [Medline] [Order article via Infotrieve]
  43. Schuuring, E., Verhoeven, E., Litvinov, S., and Michalides, R. J. (1993) Mol. Cell. Biol. 13, 2891-2898 [Abstract]
  44. Kurosaki, T., Takata, M., Yamanashi, Y., Inazu, T., Taniguchi, T., Yamamoto, T., and Yamamura, H. (1994) J. Exp. Med. 179, 1725-1729 [Abstract]
  45. Yamanashi, Y., Okada, M., Semba, T., Yamori, T., Umemori, H., Tsunasawa, S., Toyoshima, K., Kitamura, D., Watanabe, T., and Yamamoto, T. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 3631-3635 [Abstract]
  46. Benhamou, L. E., Watanabe, T., Kitamura, D., Cazenave, P. A., and Sarthou, P. (1994) Eur. J. Immunol. 24, 1993-1999 [Medline] [Order article via Infotrieve]
  47. Taniuchi, I., Kitamura, D., Maekawa, Y., Fukuda, T., Kishi, H., and Watanabe, T. (1995) EMBO J. 14, 3664-3678 [Abstract]

©1996 by The American Society for Biochemistry and Molecular Biology, Inc.